Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 15.5 Almost time to buy. 12 around the corner.

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Feb 15, 2022 11:58am

172 Views

Post# 34430244

15.5 Almost time to buy. 12 around the corner.

Same, exact same trajectory that Kalytera had before the 8 month halt and renaming.
Down she goes again. slowly but down.

Covid will end and Clitaris will come up with a new flavour and then Salzman will be paid again and round and round it goes.

If you do not already see where this is going it means..? Never mind.

<< Previous

Bullboard Posts

Next >>

Looking at: Is Taylor Swift the key to solving traffic in Toronto?